Late-stage Pipeline Event 2013

The event provided an opportunity to discuss clinical data and development plans for key late-stage compounds in the Roche development pipeline, including lampalizumab (anti-factor D) in dry AMD, etrolizumab in ulcerative colitis and selected oncology compounds.


  • Alan Hippe, Chief Financial and IT Officer - Introduction
  • Hal Barron, Head of Global Product Development, Chief Medical Officer - Pipeline update
  • Karl Mahler, Head of Investor Relations - Moderator

Webcast Replay

Link to the video webcast replay